Intermountain Healthcare Study Finds Vaping Injuries More Difficult to Diagnose During Time of COVID-19 Pandemic

by NASDAQ Market News August 20, 2020

NASDAQ Market News
Click here to email author

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Red Cross COVID-19 study shows vulnerable seniors in need of more support

Ads